Iovance Biotherapeutics Inc (NAS:IOVA)
$ 7.78 -0.36 (-4.42%) Market Cap: 2.18 Bil Enterprise Value: 2.01 Bil PE Ratio: 0 PB Ratio: 3.20 GF Score: 35/100

Iovance Biotherapeutics Inc to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer- Conference Call Transcript

Jun 29, 2021 / 08:30PM GMT
Release Date Price: $26.33 (-2.23%)
Operator

Thank you for standing by, and welcome to the Iovance Biotherapeutics update call. (Operator Instructions)

Please be advised that today's conference may be recorded. (Operator Instructions)

I would now like to hand the conference over to your host, Sara Pellegrino. Please go ahead.

Sara Pellegrino
Iovance Biotherapeutics, Inc. - VP of IR & Public Relations

Thank you. Good afternoon, and thank you for joining our conference call to discuss the initial clinical data for our TIL cell therapy LN-145 in metastatic non-small cell lung cancer, or NSCLC.

For today's agenda, our Interim President and CEO, Fred Vogt, will do a brief introduction; Dr. Friedrich Finckenstein, our Chief Medical Officer; and Dr. Madan Jagasia, our Senior Vice President, Medical Affairs, will then highlight the clinical data, and we will hold a question-and-answer session.

Before we start, I would like to remind everyone that statements made during this conference call will include forward-looking statements regarding Iovance's clinical results,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot